Abbvie Inc
NYSE: ABBV
$193.47
-$0.15 (-0.1%)
Closing Price on September 20, 2024
ABBV Articles
Halozyme Therapeutics has announced a global collaboration and license agreement with AbbVie.
Published:
ThinkstockThe American Society of Clinical Oncology’s (ASCO) annual meeting is coming to a close. Companies and cancer drug developers across the health care sector flock to this conference to...
Published:
The short interest data has been released for the May 15 settlement date and for the selected pharmaceutical stocks, short interest is mixed.
Published:
Wednesday's top analyst upgrades, downgrades and initiations include Ambarella, eBay, Rite Aid, TiVo, Yahoo, Valero Energy and Virtu Financial.
Published:
With major mergers and acquisition deals happening, and a host of clinical trials that could offer some outstanding breakthrough drug treatments, the big pharmaceutical stocks have had their fair...
Published:
The April 30 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks, short interest is mixed.
Published:
In a new report, Deutsche Bank acknowledges that while the industry has shown recent weakness, now may be just the right time to add biotech stocks.
Published:
Credit Suisse has released a report that detailed its top picks for pharmaceutical stocks for the rest of 2015.
Published:
A new report from Deutsche Bank highlights all of the known risks and focuses in on stocks that are reasonable in a pricey market.
Published:
Last Updated:
In a new report, Cowen analysts have sights set on three major pharmaceutical stocks that they expect to have rising first-quarter earnings.
Published:
24/7 Wall St. has found four good examples of blue-chip stocks that got a little tarnished recently for one reason or another, that investors may want to reexamine.
Published:
Here are three biotech stocks that a SunTrust analyst feels could be buyout candidates, in the wake of the Pharmacyclics acquisition.
Published:
News finally broke late Wednesday that there was an official buyout of Pharmacyclics in the works by AbbVie for $21 billion.
Published:
ThinkstockAfter the markets closed Monday, Express Scripts Holding Company (NASDAQ: ESRX) reported its fourth-quarter financial results as $1.39 in earnings per share (EPS) and $26.31 billion in...
Published:
One area that makes sense for growth investors is the large cap pharmaceuticals. Here are some the top pharmaceutical stocks to buy now according to Jefferies.
Published: